10270A021806-NCT04340141OpenA Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic CancerThis phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).A021806NCT04340141NationalAdultTreatmentDrug: Oxaliplatin
Drug: Irinotecan Hydrochloride
Drug: Leucovorin Calcium
Drug: Fluorouracil
Procedure: Resection
Other: Questionnaire AdministrationIIINationalPancreasThis study investigates the following conditions or diseases: Pancreatic Adenosquamous Carcinoma
Resectable Pancreatic Adenocarcinoma
Pancreatic CancerNoel, MarcusGeorgetown University Medical Center : Princess Jones, Jessica Starr; Lombardi Comprehensive Cancer Center : Princess Jones, Jessica StarrGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC); MHRI Oncology Baltimore; MHRI Washington Cancer Institute; NCA MU NCORP - 10627Jessica StarrJessica Starr+1 202-687-4739jls268@georgetown.eduClinical Research Nurse Coordinator
- 14509Princess JonesPrincess Jonespaj24@georgetown.edu
2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>